ScoreWhy is Seres Therapeutics, Inc. ?
1
The company has declared negative results in Mar'2026 after 4 consecutive positive quarters
- PRE-TAX PROFIT(Q) At USD -19 MM has Fallen at -158.13%
- NET PROFIT(Q) At USD -19 MM has Fallen at -158.13%
- RAW MATERIAL COST(Y) Grown by 11,816% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -4.99%, its profits have risen by 104.1% ; the PEG ratio of the company is 0.1
3
Below par performance in long term as well as near term
- Along with generating -4.99% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Seres Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Seres Therapeutics, Inc.
-19.12%
8.35
102.10%
S&P 500
20.78%
1.67
13.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-52.66%
EBIT Growth (5y)
-1.36%
EBIT to Interest (avg)
-23.74
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.84
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
32.94%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
1.95
EV to EBIT
-0.54
EV to EBITDA
-0.57
EV to Capital Employed
5.76
EV to Sales
50.90
PEG Ratio
0.09
Dividend Yield
NA
ROCE (Latest)
-1062.78%
ROE (Latest)
12.88%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend8What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD -42.15 MM
NET SALES(9M)
Higher at USD 1.15 MM
NET PROFIT(9M)
Higher at USD -26.13 MM
-13What is not working for the Company
PRE-TAX PROFIT(Q)
At USD -19 MM has Fallen at -158.13%
NET PROFIT(Q)
At USD -19 MM has Fallen at -158.13%
RAW MATERIAL COST(Y)
Grown by 11,816% (YoY
CASH AND EQV(HY)
Lowest at USD 75.6 MM
DEBT-EQUITY RATIO
(HY)
Highest at 191.2 %
Here's what is working for Seres Therapeutics, Inc.
Net Sales
At USD 1.15 MM has Grown at inf%
Year on Year (YoY)MOJO Watch
Sales trend is very positive
Net Sales (USD MM)
Operating Cash Flow
Highest at USD -42.15 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
Higher at USD 1.15 MM
than preceding 12 month period ended Mar 2026MOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
Net Sales (USD MM)
Here's what is not working for Seres Therapeutics, Inc.
Pre-Tax Profit
At USD -19 MM has Fallen at -158.13%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -19 MM has Fallen at -158.13%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Cash and Eqv
Lowest at USD 75.6 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Debt-Equity Ratio
Highest at 191.2 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Raw Material Cost
Grown by 11,816% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
